MagPortal.com   Clustify - document clustering
 Home  |  News Feeds  |  Stock Market  |  Newsletter  |  My Articles  |  My Account  |  Affiliate Program  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
See Also
Health
Health / Illness, Injury & Treatments
Health / Medical Practice
Science & Technology / Biology & Life Sciences
Current Medical Articles
IndustryWeek
March 17, 2010
First Up - The Audacity of Hopelessness Do our political leaders have the resolve to steer us from an unsustainable path? mark for My Articles similar articles
The Motley Fool
March 17, 2010
Brian Orelli
An Aspiring Blockbuster Novartis gets some bad clinical-trial news on its blood pressure medication. mark for My Articles similar articles
The Motley Fool
March 16, 2010
Brian Orelli
How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind. mark for My Articles similar articles
The Motley Fool
March 16, 2010
Brian Orelli
No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move mark for My Articles similar articles
Chemistry World
March 15, 2010
Matt Wilkinson
An agile future Nick Roelofs, president of Agilent Technology's life sciences group, discusses how the company is planning to ride the waves of the economic recovery. mark for My Articles similar articles
The Motley Fool
March 15, 2010
Brian Orelli
Clinical Outcomes? Who Needs 'Em. Abbott's TriCor looks good on lab tests, but that's about all. mark for My Articles similar articles
The Motley Fool
March 15, 2010
Brian Orelli
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. mark for My Articles similar articles
The Motley Fool
March 15, 2010
Brian Orelli
Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison. mark for My Articles similar articles
BusinessWeek
March 11, 2010
Margaret Cronin Fisk et al.
Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation. mark for My Articles similar articles
BusinessWeek
March 11, 2010
Ellen Gibson
The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL. mark for My Articles similar articles
BusinessWeek
March 11, 2010
Four Ways to Raise HDL Four different routes to raising good cholesterol. mark for My Articles similar articles
The Motley Fool
March 11, 2010
Jim Mueller
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? mark for My Articles similar articles
The Motley Fool
March 11, 2010
Brian Orelli
FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope. mark for My Articles similar articles
The Motley Fool
March 10, 2010
Brian Orelli
Up 160% With Room to Run You've got to love biotech and InterMune. mark for My Articles similar articles
The Motley Fool
March 10, 2010
Brian Orelli
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. mark for My Articles similar articles
The Motley Fool
March 10, 2010
Jennifer Schonberger
A Key Representative Weighs In on Financial Reform and Health Care Paul Kanjorski, D-Pa, talks about what needs to change and what needs to get done on Capitol Hill. mark for My Articles similar articles
The Motley Fool
March 9, 2010
Brian Orelli
Are Billions of Dollars in Revenue at Risk? Vaccine makers' lawsuit protection is called into question. mark for My Articles similar articles
The Motley Fool
March 9, 2010
Brian Orelli
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. mark for My Articles similar articles
The Motley Fool
March 8, 2010
Brian Orelli
Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets. mark for My Articles similar articles
The Motley Fool
March 8, 2010
Brian Orelli
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. mark for My Articles similar articles
The Motley Fool
March 5, 2010
Brian Orelli
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. mark for My Articles similar articles
BusinessWeek
March 4, 2010
Amanda Bennett
Lessons of a $618,616 Death Two years after her husband's death, the author's cover story examines the costs of keeping one man alive to fight in the face of a dismal prognosis. mark for My Articles similar articles
The Motley Fool
March 4, 2010
Brian Orelli
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. mark for My Articles similar articles
The Motley Fool
March 4, 2010
Brian Orelli
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. mark for My Articles similar articles
The Motley Fool
March 3, 2010
Brian Orelli
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. mark for My Articles similar articles
The Motley Fool
March 3, 2010
Brian Orelli
Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration. mark for My Articles similar articles
The Motley Fool
March 2, 2010
Brian Orelli
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. mark for My Articles similar articles
Inc.
March 1, 2010
Kasey Wehrum
The Business of Mission County Hospital A look at the companies that supply the California hospital with virtual records, equipment repair, and laundry services mark for My Articles similar articles
InternetNews
March 1, 2010
Major Tech Firms Back Online Health Care Cisco, Dell, Google, IBM and Microsoft all make news at the major health care show. mark for My Articles similar articles
Chemistry World
February 26, 2010
Sarah Houlton
Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain. mark for My Articles similar articles
Chemistry World
February 18, 2010
Matt Wilkinson
Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut. mark for My Articles similar articles
Chemistry World
February 4, 2010
Matt Wilkinson
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. mark for My Articles similar articles
Philanthropy
January 1, 2010
Adam Keiper
Breakthrough Medical research is dominated by government and corporate funding. How can philanthropic dollars find a distinctive niche? mark for My Articles similar articles
There are 6399 old articles available for this category.